Relationship Between Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Development of Breakthrough Infection in Solid Organ Transplant Recipients : The CONTRAST Cohort
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in solid organ transplant (SOT) recipients is associated with poorer antibody response (AbR) compared with non-SOT recipients. However, its impact on the risk of breakthrough infection (BI) has yet to be assessed.
METHODS: Single-center prospective longitudinal cohort study enrolling adult SOT recipients who received SARS-CoV-2 vaccination during a 1-year period (February 2021 - January 2022), end of follow-up April 2022. Patients were tested for AbR at multiple time points. The primary end-point was BI (laboratory-confirmed SARS-CoV-2 infection ≥14 days after the second dose). Immunization (positive AbR) was considered an intermediate state between vaccination and BI. Probabilities of being in vaccination, immunization, and BI states were obtained for each type of graft and vaccination sequence using multistate survival analysis. Then, multivariable logistic regression was performed to analyze the risk of BI related to AbR levels.
RESULTS: 614 SOT (275 kidney, 163 liver, 137 heart, 39 lung) recipients were included. Most patients (84.7%) received 3 vaccine doses. The first 2 consisted of BNT162b2 and mRNA-1273 in 73.5% and 26.5% of cases, respectively. For the third dose, mRNA-1273 was administered in 59.8% of patients. Overall, 75.4% of patients reached immunization and 18.4% developed BI. Heart transplant recipients showed the lowest probability of immunization (0.418) and the highest of BI (0.323); all mRNA-1273 vaccine sequences showed the highest probability of immunization (0.732) and the lowest of BI (0.098). Risk of BI was higher for non-high-level AbR, younger age, and shorter time from transplant.
CONCLUSIONS: SOT patients with non-high-level AbR and shorter time from transplantation and heart recipients are at highest risk of BI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 10 vom: 24. Mai, Seite 1761-1767 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bonazzetti, Cecilia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.05.2023 Date Revised 30.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciad016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351479074 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351479074 | ||
| 003 | DE-627 | ||
| 005 | 20231226051449.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351479074 | ||
| 035 | |a (NLM)36636955 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bonazzetti, Cecilia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relationship Between Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Development of Breakthrough Infection in Solid Organ Transplant Recipients |b The CONTRAST Cohort |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.05.2023 | ||
| 500 | |a Date Revised 30.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in solid organ transplant (SOT) recipients is associated with poorer antibody response (AbR) compared with non-SOT recipients. However, its impact on the risk of breakthrough infection (BI) has yet to be assessed | ||
| 520 | |a METHODS: Single-center prospective longitudinal cohort study enrolling adult SOT recipients who received SARS-CoV-2 vaccination during a 1-year period (February 2021 - January 2022), end of follow-up April 2022. Patients were tested for AbR at multiple time points. The primary end-point was BI (laboratory-confirmed SARS-CoV-2 infection ≥14 days after the second dose). Immunization (positive AbR) was considered an intermediate state between vaccination and BI. Probabilities of being in vaccination, immunization, and BI states were obtained for each type of graft and vaccination sequence using multistate survival analysis. Then, multivariable logistic regression was performed to analyze the risk of BI related to AbR levels | ||
| 520 | |a RESULTS: 614 SOT (275 kidney, 163 liver, 137 heart, 39 lung) recipients were included. Most patients (84.7%) received 3 vaccine doses. The first 2 consisted of BNT162b2 and mRNA-1273 in 73.5% and 26.5% of cases, respectively. For the third dose, mRNA-1273 was administered in 59.8% of patients. Overall, 75.4% of patients reached immunization and 18.4% developed BI. Heart transplant recipients showed the lowest probability of immunization (0.418) and the highest of BI (0.323); all mRNA-1273 vaccine sequences showed the highest probability of immunization (0.732) and the lowest of BI (0.098). Risk of BI was higher for non-high-level AbR, younger age, and shorter time from transplant | ||
| 520 | |a CONCLUSIONS: SOT patients with non-high-level AbR and shorter time from transplantation and heart recipients are at highest risk of BI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 infection | |
| 650 | 4 | |a antibody response | |
| 650 | 4 | |a solid organ transplantation | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Tazza, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Gibertoni, Dino |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquini, Zeno |e verfasserin |4 aut | |
| 700 | 1 | |a Caroccia, Natascia |e verfasserin |4 aut | |
| 700 | 1 | |a Fanì, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Fornaro, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Pascale, Renato |e verfasserin |4 aut | |
| 700 | 1 | |a Rinaldi, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Miani, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Gamberini, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Morelli, Maria Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Tamé, Mariarosa |e verfasserin |4 aut | |
| 700 | 1 | |a Busutti, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Comai, Giorgia |e verfasserin |4 aut | |
| 700 | 1 | |a Potena, Luciano |e verfasserin |4 aut | |
| 700 | 1 | |a Borgese, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Salvaterra, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzarotto, Tiziana |e verfasserin |4 aut | |
| 700 | 1 | |a Scudeller, Luigia |e verfasserin |4 aut | |
| 700 | 1 | |a Viale, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Giannella, Maddalena |e verfasserin |4 aut | |
| 700 | 0 | |a CONTRAST Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Di Chiara, Michela |e investigator |4 oth | |
| 700 | 1 | |a Giacomini, Maria Eugenia |e investigator |4 oth | |
| 700 | 1 | |a Vatamanu, Oana |e investigator |4 oth | |
| 700 | 1 | |a Marconi, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Horna, Clara Solera |e investigator |4 oth | |
| 700 | 1 | |a Campoli, Caterina |e investigator |4 oth | |
| 700 | 1 | |a Bartoletti, Michele |e investigator |4 oth | |
| 700 | 1 | |a Bussini, Linda |e investigator |4 oth | |
| 700 | 1 | |a Trapani, Fabio |e investigator |4 oth | |
| 700 | 1 | |a Attard, Luciano |e investigator |4 oth | |
| 700 | 1 | |a Gatti, Milo |e investigator |4 oth | |
| 700 | 1 | |a Gramegna, Antonio |e investigator |4 oth | |
| 700 | 1 | |a La Manna, Gaetano |e investigator |4 oth | |
| 700 | 1 | |a Grandinetti, Valeria |e investigator |4 oth | |
| 700 | 1 | |a Demetri, Marcello |e investigator |4 oth | |
| 700 | 1 | |a Barbuto, Simona |e investigator |4 oth | |
| 700 | 1 | |a Abenavoli, Chiara |e investigator |4 oth | |
| 700 | 1 | |a Vitale, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Turco, Laura |e investigator |4 oth | |
| 700 | 1 | |a Ravaioli, Matteo |e investigator |4 oth | |
| 700 | 1 | |a Cescon, Matteo |e investigator |4 oth | |
| 700 | 1 | |a Bertuzzo, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Messina, Paola |e investigator |4 oth | |
| 700 | 1 | |a Trombi, Alessandra |e investigator |4 oth | |
| 700 | 1 | |a Masetti, Marco |e investigator |4 oth | |
| 700 | 1 | |a Prestinenzi, Paola |e investigator |4 oth | |
| 700 | 1 | |a Sabatino, Mario |e investigator |4 oth | |
| 700 | 1 | |a Giovannini, Laura |e investigator |4 oth | |
| 700 | 1 | |a Alessio, Aloisio |e investigator |4 oth | |
| 700 | 1 | |a Russo, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Scuppa, Maria Francesca |e investigator |4 oth | |
| 700 | 1 | |a Dolci, Giampiero |e investigator |4 oth | |
| 700 | 1 | |a Paganelli, Gianmaria |e investigator |4 oth | |
| 700 | 1 | |a Gabrielli, Liliana |e investigator |4 oth | |
| 700 | 1 | |a Pavoni, Matteo |e investigator |4 oth | |
| 700 | 1 | |a Leone, Marta |e investigator |4 oth | |
| 700 | 1 | |a Lanna, Federica |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 10 vom: 24. Mai, Seite 1761-1767 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:10 |g day:24 |g month:05 |g pages:1761-1767 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 10 |b 24 |c 05 |h 1761-1767 | ||